Published in J Pediatr Psychol on April 01, 2008
Commentary: Children and predictive genomic testing: disease prevention, research protection, and our future. J Pediatr Psychol (2011) 1.48
Parents' attitudes toward pediatric genetic testing for common disease risk. Pediatrics (2011) 1.18
Growing up in the genomic era: implications of whole-genome sequencing for children, families, and pediatric practice. Annu Rev Genomics Hum Genet (2013) 1.11
Decisional outcomes of maternal disclosure of BRCA1/2 genetic test results to children. Cancer Epidemiol Biomarkers Prev (2013) 1.02
On the development of a decision support intervention for mothers undergoing BRCA1/2 cancer genetic testing regarding communicating test results to their children. Fam Cancer (2009) 0.95
Parenting through genetic uncertainty: themes in the disclosure of breast cancer risk information to children. Genet Test Mol Biomarkers (2011) 0.93
Commentary: trailblazing a research agenda at the interface of pediatrics and genomic discovery--a commentary on the psychological aspects of genomics and child health. J Pediatr Psychol (2009) 0.90
How Much Control Do Children and Adolescents Have over Genomic Testing, Parental Access to Their Results, and Parental Communication of Those Results to Others? J Law Med Ethics (2015) 0.83
Distress and the parenting dynamic among BRCA1/2 tested mothers and their partners. Health Psychol (2013) 0.82
Primary care providers' willingness to recommend BRCA1/2 testing to adolescents. Fam Cancer (2009) 0.81
Introduction to the special issue: psychological aspects of genomics and child health. J Pediatr Psychol (2008) 0.77
Psychometric properties of the Pediatric Testing Attitudes Scale-Diabetes (P-TAS-D) for parents of children undergoing predictive risk screening. Pediatr Diabetes (2013) 0.75
Modeling the dyadic effects of parenting, stress, and coping on parent-child communication in families tested for hereditary breast-ovarian cancer risk. Fam Cancer (2016) 0.75
Effects of undergoing multiplex genetic susceptibility testing on parent attitudes towards testing their children. Ann Behav Med (2014) 0.75
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53
A vision for the future of genomics research. Nature (2003) 14.06
Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol (2007) 7.46
Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Am J Hum Genet (1995) 6.82
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA (1996) 5.95
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol (2003) 5.69
A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer (1997) 2.53
Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol (2006) 2.53
Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol (1994) 2.52
Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol (2004) 2.25
Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers. Clin Genet (2006) 2.01
Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet (1995) 1.95
Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. Patient Educ Couns (1997) 1.75
Introduction to special issue: Evidence-based assessment in pediatric psychology. J Pediatr Psychol (2006) 1.61
An international survey of predictive genetic testing in children for adult onset conditions. Genet Med (2005) 1.56
Predictive genetic testing in young people for adult-onset conditions: where is the empirical evidence? Clin Genet (2006) 1.55
Testing adolescents for a hereditary breast cancer gene (BRCA1): respecting their autonomy is in their best interest. Arch Pediatr Adolesc Med (2000) 1.50
Parent-child factors and their effect on communicating BRCA1/2 test results to children. Patient Educ Couns (2002) 1.47
Parental communication of BRCA1/2 genetic test results to children. Patient Educ Couns (2001) 1.43
Racial differences in testing motivation and psychological distress following pretest education for BRCA1 gene testing. Cancer Epidemiol Biomarkers Prev (1999) 1.40
Family communication about positive BRCA1 and BRCA2 genetic test results. Genet Med (2004) 1.28
Genetic testing of children for adult-onset diseases: is testing in the child's best interests? Mt Sinai J Med (2006) 1.26
Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. Cancer Genet Cytogenet (2006) 1.25
Psychological issues among children of hereditary breast cancer gene (BRCA1/2) testing participants. Psychooncology (2001) 1.23
Ethical issues in genetic testing of children. Arch Pediatr Adolesc Med (2000) 1.19
Genetic professionals' reports of nondisclosure of genetic risk information within families. Eur J Hum Genet (2005) 1.18
Satisfaction with genetic counseling for BRCA1 and BRCA2 mutations among African American women. Patient Educ Couns (2006) 1.17
Is there a case in favour of predictive genetic testing in young children? Bioethics (2001) 1.15
A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships. Psychooncology (2007) 1.07
Why test children for adult-onset genetic diseases? Mt Sinai J Med (2006) 1.03
Assessment as a process in pediatric psychology. J Pediatr Psychol (1996) 1.01
Structural equation modeling in pediatric psychology: overview and review of applications. J Pediatr Psychol (2007) 0.99
Wrestling with the future: should we test children for adult-onset genetic conditions? Kennedy Inst Ethics J (1998) 0.98
Psychological and genetic counseling implications for adolescent daughters of mothers with breast cancer. Clin Genet (2005) 0.97
Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing. Ann Oncol (2006) 0.96
Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. Am J Med Genet C Semin Med Genet (2008) 0.95
Role of parenting relationship quality in communicating about maternal BRCA1/2 genetic test results with children. J Genet Couns (2008) 0.90
Attitudes regarding predictive genetic testing in minors: a survey of European clinical geneticists. Am J Med Genet C Semin Med Genet (2008) 0.90
Adolescents and genetic testing: what do they think about it? J Adolesc Health (2003) 0.89
Parental interrater reliability as a function of situational specificity and familiarity of target child. J Abnorm Child Psychol (1983) 0.89
Predictive testing of eighteen year olds: counseling challenges. J Genet Couns (2006) 0.85
Attitudes toward the genetic testing of children among adults in a Utah-based kindred tested for a BRCA1 mutation. Am J Med Genet (2000) 0.84
Attitudes of 47 mothers of pediatric oncology patients toward genetic testing for cancer predisposition. J Clin Oncol (1996) 0.83
Professional and personal attitudes about access and confidentiality in the genetic testing of children: a pilot study. Genet Test (2003) 0.83
The effects of biasing information on behavioral observations and rating scales. J Abnorm Child Psychol (1976) 0.82
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol (2006) 3.96
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 3.94
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw (2009) 2.78
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 2.65
Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol (2006) 2.53
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
The Group-Based Medical Mistrust Scale: psychometric properties and association with breast cancer screening. Prev Med (2004) 2.48
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst (2002) 2.45
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol (2005) 2.42
Identifying and characterizing adolescent smoking trajectories. Cancer Epidemiol Biomarkers Prev (2004) 2.21
All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet (2002) 2.05
Perceived disadvantages and concerns about abuses of genetic testing for cancer risk: differences across African American, Latina and Caucasian women. Patient Educ Couns (2003) 2.03
Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol (2013) 2.03
Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov (2012) 2.01
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Genetic testing: psychological aspects and implications. J Consult Clin Psychol (2002) 1.93
Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol (2014) 1.91
Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer (2014) 1.79
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med (2011) 1.70
A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol (2002) 1.69
Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. Cancer Epidemiol Biomarkers Prev (2002) 1.68
Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol (2013) 1.67
Short-term impact of cancer prevention and screening activities on quality of life. J Clin Oncol (2004) 1.66
Applying a behavioral economic framework to understanding adolescent smoking. Psychol Addict Behav (2004) 1.61
Complementary and alternative medicine use among women with breast cancer. J Clin Oncol (2002) 1.60
Intention to undergo colonoscopy screening among relatives of colorectal cancer cases: a theory-based model. Ann Behav Med (2014) 1.49
Commentary: Children and predictive genomic testing: disease prevention, research protection, and our future. J Pediatr Psychol (2011) 1.48
Educating African American men about the prostate cancer screening dilemma: a randomized intervention. Cancer Epidemiol Biomarkers Prev (2006) 1.48
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw (2014) 1.48
Parent-child factors and their effect on communicating BRCA1/2 test results to children. Patient Educ Couns (2002) 1.47
Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer (2008) 1.45
Nicotine dependence treatment for patients with cancer. Cancer (2003) 1.44
Experiences of racist events are associated with negative health consequences for African American women. J Natl Med Assoc (2003) 1.44
The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol (2006) 1.41
Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial. Genet Test (2008) 1.31
The feasibility of using natural language processing to extract clinical information from breast pathology reports. J Pathol Inform (2012) 1.30
Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol (2009) 1.30
Physicians' experiences with BRCA1/2 testing in community settings. J Clin Oncol (2008) 1.29
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29
Development and evaluation of a culturally tailored educational video: changing breast cancer-related behaviors in Chinese women. Health Educ Behav (2007) 1.28
Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat (2014) 1.28
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res (2008) 1.27
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res (2010) 1.26
F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA (2008) 1.26
The influence of culture and cancer worry on colon cancer screening among older Chinese-American women. Ethn Dis (2006) 1.25
Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol (2006) 1.22
The development of a web- and a print-based decision aid for prostate cancer screening. BMC Med Inform Decis Mak (2010) 1.21
Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results. Am J Med Genet C Semin Med Genet (2006) 1.21
Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat (2006) 1.20
Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control (2005) 1.20
Online advertising to reach and recruit Latino smokers to an internet cessation program: impact and costs. J Med Internet Res (2012) 1.20
Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res (2006) 1.19
Randomized controlled trial of a psychosocial telephone counseling intervention in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.19
The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members. J Clin Oncol (2006) 1.18
Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol (2008) 1.18
Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. Psychooncology (2009) 1.17
Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol (2009) 1.17
BRCA1/2 genetic testing in the community setting. J Clin Oncol (2002) 1.17
Disparities in cervical cancer screening between Asian American and Non-Hispanic white women. Cancer Epidemiol Biomarkers Prev (2008) 1.16
Information needs of mothers regarding communicating BRCA1/2 cancer genetic test results to their children. Genet Test (2007) 1.16
The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat (2012) 1.15
Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization. J Gen Intern Med (2009) 1.14
Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell (2013) 1.14
Patient satisfaction with cancer genetic counseling: a psychometric analysis of the Genetic Counseling Satisfaction Scale. J Genet Couns (2004) 1.14
Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases. Cancer Res (2009) 1.14
Breast Cancer Risk Reduction, Version 2.2015. J Natl Compr Canc Netw (2015) 1.12
Effects of inattention and hyperactivity/impulsivity symptoms on development of nicotine dependence from mid adolescence to young adulthood. J Pediatr Psychol (2007) 1.10
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat (2010) 1.10
Accuracy of cancer family histories: comparison of two breast cancer syndromes. Genet Test (2004) 1.09
Re: the impact of prior authorization requirements on primary care physicians' offices: report of two parallel network studies. J Am Board Fam Med (2013) 1.09
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat (2012) 1.09
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer (2007) 1.09
Knowledge, cultural, and attitudinal barriers to mammography screening among nonadherent immigrant Chinese women: ever versus never screened status. Cancer (2009) 1.08
Developing and validating a measure of Chinese cultural views of health and cancer. Health Educ Behav (2007) 1.08
Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology (2006) 1.08
Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice. Cancer Epidemiol Biomarkers Prev (2012) 1.08
Predictors of participation in a smoking cessation program among young adult smokers. Cancer Epidemiol Biomarkers Prev (2007) 1.06